In late 2002, a sensational article in the New York Times, depicting the experience of James Quinn and death after the AbioCor artificial heart raises questions about the processing of Abiomed informed consent related to clinical trials. At the same time, investor confidence in the company's weakening due to the apparent stall in the course of clinical trials. This case illustrates the processing of B Abiomed about the situation, along with comments from the audience, including close to the Quinn case, as well as medical ethics and financial investors and analysts. Analysis of election Abiomed shows obvious strategy of the company as one of downplaying the importance of this article, the message and strengthens investor protection falling share price of the company. In the case also shows how the company has changed the 30-day "quiet period", which became a lightning rod in the media. "Hide
by Elizabeth A. Powell, Rebecca A. Goldberg Source: Darden School of Business 6 pages. Publication Date: January 25, 2010. Prod. #: UV4247-PDF-ENG
